Melanoma

P1, N=61, Active, not recruiting, Institute of Cancer Research, United Kingdom | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026

P=N/A, N=100000, Active, not recruiting, Institut National de la Santé Et de la Recherche Médicale, France | Trial completion date: Dec 2025 --> Dec 2046

Comparable trends were observed for Matrigel-coated substrates, indicating that microscale topography exerted consistent effects on B16-F10 melanoma cell responses across the tested extracellular matrix conditions. Collectively, our results demonstrate that surface topography with narrow pillar microstructures is associated with topography-dependent changes in cell behavior and melanogenic activity, providing insights into how microscale topographic confinement influences melanoma cell morphology and melanogenic activity.

Patients who died within 30 days had significantly shorter progression-free survival (1.18 vs. 4.63 months) and overall survival (2.30 vs. 14.39 months) compared with survivors. These findings suggest that routine assessment of inflammatory and nutritional biomarkers alongside tumor burden parameters may help identify patients at high risk of early mortality and inform the timing of supportive care in ICI-treated populations.

Notably, ceramide induced by GH01 interacted with mitochondria, thus releasing cytochrome c, which in turn activated caspase-9 and caspase-3, ultimately triggering cellular apoptosis. Additionally, the supplementation of inhibitors of caspase-3 and exogenous ceramide further confirmed the above apoptosis mechanism.

Overall, SC18 disrupted mitochondrial metabolism, induced oxidative stress, and impaired survival and motility pathways, with more pronounced effects in low/amelanotic than in melanotic melanoma cells. Together, these findings support the further development of SC18 as a mitochondrial metabolic disruptor that targets redox vulnerabilities in melanoma.

Additionally, they bolster the intracellular antioxidant defense system. These findings unveil a sophisticated regulatory network and suggest that with strict control of systemic exposure through optimized topical formulations, these FDA-approved agents could be further investigated as potential localized treatments for pigmentary disorders.

In this retrospective cohort study, clinical data (morphine equivalent daily dose, demographics) and genetic data (single-nucleotide polymorphisms) were analyzed across 31 candidate loci...Ultimately, tumor bank DNA is a feasible resource for pharmacogenetic research. Identified loci may contribute to variability in opioid response and support future personalized pain management strategies.

P2, N=29, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028

P2, N=29, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: May 2026 --> May 2031

P=N/A, N=258, Not yet recruiting, Herlev Hospital | Trial completion date: Jun 2027 --> Dec 2027

Conversely, dietary CLPO enhanced immune-antioxidant function, restored hematological profiles, mitigated gene expression disturbances, and preserved splenic structure. Overall, dietary CLPO supplementation significantly attenuated several adverse effects under the present experimental conditions, highlighting its potential as a protective additive in aquafeeds.